進行固形腫瘍における抗GD2 ADC M3554

基本情報

NCT ID: NCT06641908
ステータス: 募集中
試験のフェーズ: 第1相
試験タイプ: 介入
目標被験者数: 52
治験依頼者名: EMD Serono

概要

The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months

対象疾患

進行固形腫瘍

介入

M3554(DRUG)

依頼者（Sponsor）

Merck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, Germany(INDUSTRY)

Emd Serono Research & Development Institute(INDUSTRY)

実施施設 (2)

National Cancer Center Hospital

Chūōku, Japan(RECRUITING)

国立研究開発法人国立がん研究センター中央病院

Chūōku, Japan(RECRUITING)